Iterum Therapeutics plc (ITRMF) Cash & Equivalents (2017 - 2025)

Iterum Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $11.0 million in Q3 2025.

• On a quarterly basis, Cash & Equivalents fell 17.93% year-over-year to $11.0 million in Q3 2025; TTM through Sep 2025 was $11.0 million, a 17.93% decrease from a year earlier, with the FY2024 full-year figure at $24.1 million, up 297.38% from the prior year.
• Cash & Equivalents was $11.0 million for Q3 2025 at Iterum Therapeutics, down from $13.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $66.6 million in Q1 2021, with the low at $4.8 million in Q3 2023.
• Average Cash & Equivalents over 5 years is $19.8 million, with a median of $13.7 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents soared 319.86% in 2021, then slumped 76.49% in 2023.
• Over 5 years, Cash & Equivalents stood at $27.4 million in 2021, then dropped by 23.15% to $21.1 million in 2022, then tumbled by 71.22% to $6.1 million in 2023, then surged by 297.38% to $24.1 million in 2024, then sank by 54.4% to $11.0 million in 2025.
• The last three Cash & Equivalents figures came in at $11.0 million (Q3 2025), $13.0 million (Q2 2025), and $12.7 million (Q1 2025), per Business Quant data.